When Knee Osteoarthritis Involves Inflammation
Knee osteoarthritis is a common joint condition that can cause pain, stiffness, swelling, and reduced mobility. While it is often thought of as cartilage “wear and tear,” osteoarthritis is more complex than that. Inflammation inside the joint can also play an important role.
One form of joint inflammation seen in osteoarthritis is synovitis. This happens when the synovium, the thin lining inside the joint, becomes inflamed. Synovitis can contribute to swelling, discomfort, stiffness, and worsening joint symptoms.
Because inflammation can affect how osteoarthritis progresses, researchers are studying regenerative approaches that may help support a healthier joint environment.
Why Researchers Studied UC-MSCs
Umbilical cord-derived mesenchymal stem cells, or UC-MSCs, are being studied in regenerative medicine because they release helpful signals that may influence inflammation, immune activity, cartilage health, and tissue repair.
Rather than simply replacing damaged tissue, MSCs may work through cell signaling. This means they release molecules that communicate with nearby cells and may help guide the joint toward a more balanced, repair-supportive state.
For knee osteoarthritis, researchers are especially interested in whether UC-MSCs may help:
- Reduce inflammatory activity inside the joint
- Support healthier cartilage cell function
- Improve pain and daily movement
- Help protect the joint environment
- Support quality of life in patients with ongoing symptoms
A Closer Look at the Trial
This study was a randomized, double-blind, placebo-controlled clinical trial. That means participants were randomly assigned to treatment groups, and both the patients and evaluators did not know which treatment each person received.
The trial included 55 participants with knee osteoarthritis. Patients were placed into one of three groups:
- Placebo injection
- Hyaluronic acid injection
- UC-MSC injection
The UC-MSC group received a single ultrasound-guided injection into the knee joint. The dose was 2 × 10⁷ UC-MSCs.
Participants were followed for 24 weeks, or about 6 months. Researchers evaluated safety, pain, knee function, quality of life, and MRI findings. They used common assessment tools such as VAS pain scores, WOMAC scores, KSS scores, EQ-5D quality-of-life scores, and MRI evaluation of joint structures.
What the Study Found
The study reported encouraging safety findings. No serious treatment-related adverse events were observed. Reported side effects were generally mild or moderate, with temporary injection-related pain being the most common issue. This discomfort resolved within 2 days.
When looking at all participants, UC-MSC treatment showed greater improvement in pain and quality-of-life scores compared with placebo and hyaluronic acid, although some differences were not statistically significant. The most meaningful findings appeared in patients who had knee osteoarthritis with synovitis, especially those with moderate to severe pain.
In this group, UC-MSC treatment was associated with significant improvement in synovitis on MRI after 24 weeks. This means the inflamed joint lining appeared improved after treatment. Patients in the UC-MSC group also showed significant improvements in pain, WOMAC scores, and EQ-5D quality-of-life scores at the 6-month follow-up.
MRI did not show major changes in cartilage or bone marrow lesions during the 6-month study period, but the improvement in synovitis was an important finding because inflammation is closely connected to osteoarthritis symptoms.
How UC-MSCs May Support the Joint
Osteoarthritis involves several overlapping issues, including cartilage breakdown, inflammation, joint stress, and changes in the tissue environment. When synovitis is present, inflammation may further contribute to pain and joint dysfunction.
UC-MSCs may help by releasing signals that calm excessive inflammation and support healthier communication between cells inside the joint. These signals may include growth factors, cytokines, and extracellular vesicles that influence immune activity and tissue repair.
In simpler terms, UC-MSCs may help the joint environment become less inflamed and more supportive of function. This may be especially helpful for patients whose osteoarthritis symptoms are strongly connected to synovitis.
Why This Research Matters
This study is meaningful because it focused on a specific subgroup of knee osteoarthritis patients: those with synovitis. Not all osteoarthritis is the same, and patients with joint inflammation may respond differently to certain therapies.
The findings suggest that UC-MSCs may be especially promising for knee osteoarthritis cases where inflammation is part of the problem. This supports the idea that regenerative medicine may become more personalized in the future, with treatments better matched to a patient’s joint condition, imaging findings, and symptom pattern.
The study also adds to growing clinical research on umbilical cord-derived MSCs as a potential regenerative option for joint support, inflammation balance, and improved mobility.
Looking Forward
Future studies with larger patient groups and longer follow-up periods will help confirm these findings and better understand how long the benefits may last. Longer studies may also help researchers evaluate whether UC-MSCs can influence cartilage structure or other joint changes over time.
As research continues, UC-MSC therapy may become an important area of study for patients with knee osteoarthritis, particularly when inflammation inside the joint contributes to pain and reduced function.
Main Takeaway
This randomized controlled trial provides encouraging evidence that intra-articular UC-MSC injection may support patients with knee osteoarthritis and synovitis. The treatment was well tolerated and was associated with improvement in synovitis, pain, knee function, and quality of life in patients with inflammatory knee osteoarthritis and moderate to severe pain.
While more research is needed, this study highlights the potential of UC-MSCs as a regenerative approach focused on reducing inflammation and supporting a healthier joint environment.
Source
Tong W, Shi Y, Wu D, Jia J, Xiang E, Xu D, Rao W, Hu Q, Liao Q, Xiao C, Zheng S, Xu W, et al. Intra-articular injection of umbilical cord–derived mesenchymal stem cells is safe and effective for moderate to severe knee osteoarthritis with synovitis: a double-blinded and randomized controlled trial. BMC Musculoskeletal Disorders. 2026;27:84. doi: 10.1186/s12891-025-09440-y. Available from: https://link.springer.com/article/10.1186/s12891-025-09440-y
Related Treatment Pages